SeaStar Medical showcases new data from SAVE Registry

SeaStar Medical (ICU) announced the presentations of new SAVE Registry data and investigator led research on the mechanism of action of the selective cytopheretic device therapy at the 31st International Conference on Advances in Critical Care Nephrology. The company said preliminary outcomes analysis from the SAVE Registry show survival rates of 69%, consistent with previous clinical trial experience, with no device-related adverse events. “We are establishing a growing presence in the pediatric AKI community with strong support from experts in the field,” said Kevin Chung, chief medical officer of SeaStar Medical. “Our goal is to expand awareness and treatment options for this serious, life-threatening condition. Every one of these kids deserves the best possible chance of survival, and with historical mortality rates of 50%, we believe that is just not good enough. We thank the pediatric AKI health care community for their dedication to these kids, and to searching for all available options to give sick children a chance.”